Update on the combination of myo-inositol/d-chiro-inositol for the treatment of polycystic ovary syndrome

被引：4

作者：

Lete, Inaki ^{[1
,2
]}

Martinez, Ainara ^{[1
]}

Lasaga, Irene ^{[1
]}

Centurion, Eva ^{[1
]}

Vesga, Amaia ^{[1
]}

机构：

[1] Araba Univ Hosp, Obstet & Gynaecol Clin Management Unit, Vitoria, Spain

[2] Araba Univ Hosp, Obstet & Gynaecol Clin Management Unit, Txagorritxu Campus, Vitoria 01009, Spain

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 2024年 / 40卷 / 01期

关键词：

Polycystic ovary syndrome; inositol; MYO/DCI ratio; HUMAN THECAL CELLS; GROWTH-FACTOR-I; FOLLICULAR-FLUID; OOCYTE QUALITY; THERAPEUTIC APPROACH; ANDROGEN PRODUCTION; GENE-PRODUCTS; IGF-II; MYOINOSITOL; WOMEN;

D O I：

10.1080/09513590.2023.2301554

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this article, we present a narrative review on the use of inositol in the treatment of polycystic ovary syndrome (PCOS). Of the different inositols that exist, only myo-inositol (MYO) and D-chiro inositol (DCI) have been studied in the treatment of PCOS. The results of the studies show that there is insufficient or controversial evidence to recommend the use of DCI alone, while MYO alone shows positive results and, above all, the MYO/DCI combination is effective when used at a ratio of at least 40:1, but there is enough rationale to further study ratios such as 66:1 to 100:1 as other possible effective combinations.

引用

页数：5

共 50 条

[31] The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios
Nordio, M.
Basciani, S.
Camajani, E.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2019, 23 (12) : 5512 - 5521
[32] Does ovary need D-chiro-inositol?
Isabella R.
Raffone E.
Journal of Ovarian Research, 5 (1)
[33] May myo-inositol andd-chiro-inositol (40:1) treatment be a good option on normal-weighted polycystic ovary syndrome patients without insulin resistance?
Colak, Eser
Ozcimen, Emel Ebru
Tohma, Yusuf Aytac
Ceran, Mehmet Ufuk
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2020, 46 (12) : 2605 - 2611
[34] The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes
Pintaudi, Basilio
Di Vieste, Giacoma
Bonomo, Matteo
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2016, 2016
[35] Myo-inositol products in polycystic ovary syndrome (PCOS) treatment: quality, labeling accuracy, and cost comparison
Papaleo, E.
Molgora, M.
Quaranta, L.
Pellegrino, M.
De Michele, F.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2011, 15 (02) : 165 - 174
[36] Strategy to improve the female fertility in the general gynecologist's office: use of a nutritional supplement based on myo-inositol/D-chiro-inositol and antioxidants
Mendoza, Nicolas
Losa, Fernando
Palacios, Santiago
GYNECOLOGICAL ENDOCRINOLOGY, 2022, 38 (04) : 275 - 278
[37] Myo-Inositol and D-Chiro-Inositol Reduce DHT-Stimulated Changes in the Steroidogenic Activity of Adult Granulosa Cell Tumors
Wojciechowska, Anna Maria
Zajac, Paulina
Gogola-Mruk, Justyna
Kowalik, Magdalena Karolina
Ptak, Anna
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (20)
[38] Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome
Pacchiarotti, Alessandro
Carlomagno, Gianfranco
Antonini, Gabriele
Pacchiarotti, Arianna
GYNECOLOGICAL ENDOCRINOLOGY, 2016, 32 (01) : 69 - 73
[39] Potential role of D-chiro-inositol in reducing oxidative stress in the blood of nonobese women with polycystic ovary syndrome
Simic, Dusan
Turnic, Tamara Nikolic
Dimitrijevic, Aleksandra
Zivadinovic, Aleksandar
Milosevic-Stevanovic, Jelena
Djuric, Dusan
Zivkovic, Vladimir
Jakovljevic, Vladimir
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2022, 100 (07) : 629 - 636
[40] Myo-inositol for insulin resistance, metabolic syndrome, polycystic ovary syndrome and gestational diabetes
DiNicolantonio, James J.
O'Keefe, James
OPEN HEART, 2022, 9 (01):

← 1 2 3 4 5 →